Endocannabinoids Control Platelet Activation and Limit Aggregate Formation under Flow

Endocannabinoids Control Platelet Activation and Limit Aggregate Formation under Flow

BACKGROUND The endocannabinoid system has previously been implicated in the regulation of neurons and inflammatory cells. Additionally, it has been reported that endocannabinoid receptors are present on circulating platelets, but there has been conflicting evidence on their contribution to platelet function. OBJECTIVES Our aim was to examine the role of endocannabinoids in platelet function i...

Renal Denervation Reduces Monocyte Activation and Monocyte–Platelet Aggregate Formation

Hypertension contributes significantly to the high cardiovascular morbidity and mortality rates worldwide. While acknowledging the complexity and multifactorial pathogenesis of hypertension, it has been suggested that activation of the sympathetic nervous system (SNS) is an important contributor in at least 50% of cases. Persistent sympathetic activation initiates and sustains elevated blood pr...

Platelet activation and platelet- monocyte aggregate formation induced by the atherosclerotic plaque lipid lysophosphatidic acid

GPVI and α2β1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow

GPVI and α2β1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow Kendra L. Sarratt, Hong Chen, Mary M. Zutter, Samuel A. Santoro, Daniel A. Hammer, and Mark L. Kahn From the Department of Bioengineering and Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA; Department of Pathology, Vanderbilt Univers...

The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.

BACKGROUND Treatment of chronic myelogenous leukemia (CML) with the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib significantly improves patient outcomes. As some patients are unresponsive to imatinib, next generation BCR-ABL inhibitors such as nilotinib have been developed to treat patients with imatinib-resistant CML. The use of some BCR-ABL inhibitors has been associated with bleeding dia...